摘要
2004年12月，美国FDA批准Genzyme公司的clofarabine（商品名Clolar）治疗1～21岁顽固性或复发性急性淋巴细胞白血病（ALL）患者。氯法拉滨为10多年来首个获准专门用于儿童白血病治疗的新药。本文介绍了氯法拉滨的品种特点、国内外的研究现状及临床意义.
Clofarabine （Clolar^TM） received an approval by FDA at the end of 2004 for the treatment of paediatric patients （1-21 years old ） who have refractory or relapsed acute lymphoblastic leukemia （ALL）. It is the first drug that was approved for paediatric leukemia in the last decade. This article introduced the features, clinical significance and research status at home and abroad of clofarabine.
出处
《药学与临床研究》
2009年第2期131-134,共4页
Pharmaceutical and Clinical Research
